Skip to main content
    B

    Brainsway Ltd (BWAY)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $10.11
    -0.14 (-1.37%)

    Market Cap: $406.96M

    Last updated: Nov 17, 2026 at 10:59 AM ET

    Brainsway Ltd (BWAY) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Brainsway reported EPS of $0.10, below the $0.12 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    48%(15/31)
    Avg Surprise
    +23.40%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$0.22
    Range$0.21 - $0.23
    3 analysts
    Revenue Consensus
    $56.22M
    Range$54.02M - $57.88M
    3 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$0.12
    Range$0.09 - $0.14
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.11+7.8%
    60d ago$0.11+7.8%
    30d ago$0.11+7.8%
    7d ago$0.11+7.8%
    Current$0.12
    Revenue Consensus
    $19.58M
    Range$18.50M - $20.44M
    3 analysts

    Next Report

    Analysts' consensus for the quarter ending Dec 31, 2026 is 266.7% above the $0.06 reported for the quarter ended Dec 31, 2025.

    BWAY's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    BWAY Earnings Call

    The latest BWAY earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 31 quarters below that had an estimate, BWAY beat 15, missed 7 and matched 9. Revenue for the quarter ended Sep 30, 2026 was $18.00M, up 33.2% from $13.51M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.10$0.12$0.07 - $0.12-16.67%Miss+400.0%31 up, 1 downNov 10, 2026$18.00M
    Jun 30, 2026$0.14$0.10$0.05 - $0.10+40.00%Beat+366.7%31 up, 0 downAug 12, 2026$17.40M
    Mar 31, 2026$0.06$0.05$0.03 - $0.06+20.00%Beat+500.0%33 up, 0 downMay 13, 2026$15.53M
    Dec 31, 2025$0.06$0.05N/A+39.91%Beat+59.5%30 up, 1 downMar 11, 2026$14.54M
    Sep 30, 2025$0.02$0.02$0.02 - $0.030.00%In line+100.0%43 up, 0 downNov 11, 2025$13.51M
    Jun 30, 2025$0.03$0.02$0.02 - $0.05+50.00%Beat+200.0%42 up, 1 downAug 13, 2025$12.63M
    Mar 31, 2025$0.01$0.01$0.01 - $0.030.00%In line+49.3%31 up, 0 downMay 13, 2025$11.54M
    Dec 31, 2024$0.04$0.04N/A0.00%In line+426.3%11 up, 0 downMar 11, 2025$11.41M
    Sep 30, 2024$0.01$0.01$0.01 - $0.020.00%In lineN/A30 up, 0 downNov 12, 2024$10.50M
    Jun 30, 2024$0.01-$0.01N/A+200.00%BeatN/A10 up, 0 downAug 6, 2024$10.01M
    Mar 31, 2024$0.01-$0.01-$0.01 - -$0.01+167.00%BeatN/A10 up, 0 downMay 8, 2024$9.10M
    Dec 31, 2023$0.01-$0.01-$0.01 - -$0.01+176.00%BeatN/A20 up, 0 downMar 6, 2024$9.03M
    Sep 30, 2023-$0.02-$0.02-$0.03 - -$0.020.00%In lineN/A20 up, 0 downNov 15, 2023$8.30M
    Jun 30, 2023-$0.02-$0.02N/A0.00%In lineN/AN/A0 up, 0 downAug 9, 2023$7.83M
    Mar 31, 2023-$0.04-$0.05-$0.06 - -$0.05+20.00%BeatN/A20 up, 0 downMay 17, 2023$6.63M
    Dec 31, 2022-$0.24-$0.26N/A+7.69%BeatN/A20 up, 0 downMar 15, 2023$6.03M
    Sep 30, 2022-$0.07-$0.06-$0.06 - -$0.06-16.67%MissN/A20 up, 1 downNov 16, 2022$5.17M
    Jun 30, 2022-$0.04-$0.03N/A-33.33%MissN/AN/AN/AAug 10, 2022$8.01M
    Mar 31, 2022-$0.03-$0.04N/A+25.00%BeatN/AN/A0 up, 0 downMay 11, 2022$7.97M
    Dec 31, 2021-$0.04-$0.05N/A+20.00%BeatN/AN/A0 up, 0 downMar 9, 2022$8.47M
    Sep 30, 2021-$0.02-$0.02N/A-33.33%MissN/AN/A0 up, 0 downNov 17, 2021$8.06M
    Jun 30, 2021-$0.03-$0.03N/A0.00%In lineN/AN/A0 up, 0 downAug 11, 2021$7.00M
    Mar 31, 2021-$0.05-$0.06-$0.06 - -$0.06+16.67%BeatN/A1N/AMay 20, 2021$6.12M
    Dec 31, 2020-$0.04-$0.04N/A-14.29%MissN/A1N/AMar 24, 2021$7.07M
    Sep 30, 2020-$0.02-$0.02N/A-33.33%MissN/AN/AN/ANov 18, 2020$6.01M
    Jun 30, 2020-$0.01-$0.06-$0.08 - -$0.06+83.33%BeatN/A2N/AAug 12, 2020$4.82M
    Mar 31, 2020-$0.30-$0.30N/A0.00%In lineN/A4N/AJun 24, 2020$4.16M
    Dec 31, 2019-$0.05-$0.06-$0.06 - -$0.05+16.67%BeatN/A4N/AMar 23, 2020$6.29M
    Sep 30, 2019-$0.12-$0.12-$0.12 - -$0.110.00%In lineN/A4N/ANov 25, 2019$5.93M
    Jun 30, 2019-$0.34-$0.26N/A-30.77%MissN/A3N/AAug 26, 2019$5.70M
    Mar 31, 2019-$0.11-$0.14N/A+21.43%BeatN/AN/AN/AMay 29, 2019$5.18M
    Dec 31, 2018-$0.12N/AN/AN/AN/AN/AN/AN/AFeb 27, 2019$4.77M
    Sep 30, 2018-$0.09N/AN/AN/AN/AN/AN/AN/ASep 30, 2018$4.29M
    Jun 30, 2018-$0.11N/AN/AN/AN/AN/AN/AN/AJun 30, 2018$3.73M
    Mar 31, 2018-$0.06N/AN/AN/AN/AN/AN/AN/AMar 31, 2018$3.60M
    Dec 31, 2017-$0.17N/AN/AN/AN/AN/AN/AN/ADec 31, 2017$3.60M
    Sep 30, 2017-$0.12N/AN/AN/AN/AN/AN/AN/ASep 30, 2017$3.02M
    Jun 30, 2017-$0.03N/AN/AN/AN/A-157.8%N/AN/AJun 30, 2017$2.38M
    Mar 31, 2017-$0.13N/AN/AN/AN/AN/AN/AN/AMar 31, 2017$2.15M
    Dec 31, 2016-$0.10N/AN/AN/AN/AN/AN/AN/ADec 31, 2016$2.88M
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.12, up 85.6% from the year before. It was -$0.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.12+85.6%
    Dec 31, 2024$0.07N/A
    Dec 31, 2023-$0.07N/A
    Dec 31, 2022-$0.38N/A
    Dec 31, 2021-$0.14N/A
    Dec 31, 2020-$0.37N/A
    Dec 31, 2019-$0.62N/A
    Dec 31, 2018-$0.12N/A
    Dec 31, 2017-$0.48N/A
    Dec 31, 2016-$0.17N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,000 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,9736
    2026Q2Jun 30, 20263,8986
    2026Q1Mar 31, 20264,1856
    2025Q3Sep 30, 20253,3037
    2025Q2Jun 30, 20252,8607
    2025Q1Mar 31, 20252,9816
    2024Q4Dec 31, 20244,0108
    2024Q3Sep 30, 20243,0897

    2026Q3 Earnings Call

    Opening remarks

    Hadar Levy CEO Thank you, operator, and welcome, everyone. I'm pleased to report another strong quarter for BrainsWay, reflecting continued execution of our growth strategy, expanding adoption of Deep TMS, and further progress toward building a scalable and profitable business. Our ambition extends beyond selling medical devices. We are building a leading neurostimulation platform in mental health, supported by differentiated technology, expanding clinical indications, broader reimbursement, strategic partnerships, and an increasingly predictable recurring revenue model. During the third quarter, we shipped 130 Deep TMS systems, representing 44% year-over-year growth. Our global installed base now exceeds 2,000 systems, further expanding patient access to Deep TMS while creating additional opportunities for commercial leverage across our existing customers. Our financial results reflect this momentum, with revenue growing 34% year-over-year and remaining performance obligations reaching approximately $85 million, an increase of 31% compared with the prior year. We believe the continued growth in RPO demonstrates both strong market demand and the success of our recurring revenue model. Our multiyear agreements, high customer retention, and growing enterprise relationships provide greater visibility into future revenue while allowing us to deliver comprehensive, high-quality support to our customers. Importantly, we continue to demonstrate our ability to combine strong growth with operational discipline and profitability. Turning to clinical development, Deep TMS continued to build on one of the industry's most extensive bodies of peer-reviewed evidence, supported by multiple FDA clearances. During the quarter, we announced a peer-reviewed secondary analysis of our randomized clinical trial comparing SWIFT with standard once-daily Deep TMS. Among 89 patients with major depressive disorder, the number experiencing suicidal ideation declined from 20 at baseline to 6 after six weeks, representing a 70% relative reduction, with improvements observed across both protocols. We also announced encouraging results from a pilot study involving 12 patients with depression and early-stage Alzheimer's disease, reporting an 83% response rate and a 50% remission rate in depressive symptoms. While preliminary, the findings support further investigation. Deep TMS is not FDA-cleared for suicidal ideation or to treat Alzheimer's disease. Regarding PTSD among patients with coexisting depression, we continue to work through the regulatory review process. We believe a potential clearance would represent an important development, potentially allowing providers to address another significant unmet medical need using their existing Deep TMS system. Alongside this clinical advantage, we continue to make significant progress in reimbursement. Following the quarter, we announced that more than 70 million covered lives in the U.S. now have access to reimbursement policies covering our SWIFT accelerated protocol. We have also expanded OCD reimbursement coverage to approximately 180 million lives, while our adolescent depression clearance creates another opportunity to broaden access. We believe SWIFT represents one of our most significant long-term growth opportunities.

    Frequently Asked Questions About BWAY

    Did BWAY beat earnings estimates last quarter?

    No. Brainsway reported EPS of $0.10 for the quarter ended Sep 30, 2026, below the $0.12 estimate by 16.67%.

    What EPS do analysts expect from BWAY next quarter?

    The consensus EPS estimate for Brainsway for the quarter ending Dec 31, 2026 is $0.22 from 3 analysts, with estimates from $0.21 to $0.23.

    How often does BWAY beat earnings estimates?

    Brainsway beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +16.66%.